Author

Friedman Gary

Institution: Pfizer (United States)

Observed institution: Pfizer (United States)

OpenAlex ID: A5065701038

P034 Assessment of age as a risk factor for adverse events in patients from the tofacitinib ulcerative colitis clinical program

2019 · Lichtenstein Gary, Bressler Brian, et al. · The American Journal of Gastroenterology · 2

P036 Impact of prior immunosuppressant and tumor necrosis factor inhibitor therapies on tofacitinib efficacy and safety in patients with ulcerative colitis

2019 · Lichtenstein Gary, Cohen Benjamin, et al. · The American Journal of Gastroenterology

Works count: 2

Citation count: 2

H-index: 1

I10-index: